Bharat Biotech International Limited (BBIL) will roll out its intranasal Covid-19 vaccine iNcovacc in the fourth week of January 2023. The vaccine is now available on CoWin platform.
The vaccine has been priced at ₹800 per dose for private healthcare providers and ₹325 per dose for governments, excluding 5 per cent GST, the company said in a statement on Tuesday.
On a comparative note, Corbevax of Biological E costs ₹250 per dose at the private vaccination centres while Covishield of Serum Institute and Covaxin of Bharat Biotech are priced at ₹225 per dose at private health facilities.
Krishna Ella, Executive Chairman of BBIL, said; “We have achieved the goals we set for ourselves during this pandemic. We have developed Covaxin and iNcovacc, two Covid vaccines from two different platforms, with two different delivery systems.”
India ups Covid preparedness; Karnataka brings back mask mandate in public placesFresh infections in the last 24 hours in India on Monday stood at 196
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunisation during public health emergencies and pandemics, he added.
As a needle-less vaccination, iNcovacc will be India’s first such booster dose. India will now have more options when it comes to third dose or precautionary doses.
Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including in States such as Gujarat, Karnataka, Maharashtra and Telangana.
Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNcovacc. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.